Antileishmanial compositions and methods of use
In one aspect, the invention relates methods and compositions for treating parasitic diseases, for example, leishmaniasis. In a further aspect, the compounds of the methods and compositions are isolated from Pentalinon andrieuxii . This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the formula:
wherein each of R 4a and R 4b is independently selected from hydrogen and C 1 -C 12 alkyl, and each of R 6a and R 6b is independently selected from hydrogen and C 1 -C 12 alkyl;
or a pharmaceutically acceptable salt, solvate, or polymorph thereof;
wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liposome, nanoparticle, microparticle, cyclodextrin, nanoemulsion, microemulsion, polymersome, surfactant, biocompatible organic solvent, and micelle,
wherein the composition is sterile.
2. The composition of claim 1 , wherein the compound is selected from:
3. The composition of claim 1 , wherein the compound is:
4. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is a liposome.
5. The composition of claim 4 , wherein the liposome comprises a phospholipid.
6. The composition of claim 4 , wherein the liposome comprises one or more lipids selected from phosphatidylcholine, tocopherol, cholesterol, and 1,2-distearoyl-phosphatidyl ethanolamine-methyl-polyethylene glycol conjugate.
7. The composition of claim 4 , wherein the liposome comprises phosphatidylcholine and tocopherol.
8. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is a biocompatible organic solvent comprising propylene glycol, polyethylene glycol, ethanol, dimethyl sulfoxide, N-methyl-2-pyrrolidone, glycofurol, 2,2-dimethyl-1,3-dioxolane-4-methanol (Solketal™), glycerol formal, acetone tetrahydrofurfuryl alcohol, diglyme, dimethyl isosorbide, cremophor, or ethyl lactate.
9. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is a surfactant comprising a phospholipid, a poloxamer, or a polysorbate.
10. The composition of claim 1 , wherein the composition is in the form of a powder, a granule, a solution, a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion.
11. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is a microemulsion or nanoemulsion.
12. The composition of claim 11 , wherein the microemulsion or nanoemulsion comprises an oil, surfactant, and aqueous phase.
13. The composition of claim 12 , wherein the oil comprises soybean oil or castor oil.
14. The composition of claim 12 , wherein the surfactant comprises tween or span.
15. The composition of claim 1 , further comprising at least one additional therapeutic agent.
16. The composition of claim 15 , wherein the at least one additional therapeutic agent comprises a vaccine.